Found: 241
Select item for more details and to access through your institution.
BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 8, p. 1632, doi. 10.1002/ajh.27359
- By:
- Publication type:
- Article
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 7, p. 2299, doi. 10.1007/s00277-024-05665-4
- By:
- Publication type:
- Article
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 6, p. 938, doi. 10.1111/ejh.14188
- By:
- Publication type:
- Article
Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort.
- Published in:
- European Journal of Haematology, 2024, v. 112, n. 4, p. 654, doi. 10.1111/ejh.14155
- By:
- Publication type:
- Article
How to improve treatment‐free remission eligibility in chronic myeloid leukaemia?
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 2, p. 434, doi. 10.1111/bjh.19269
- By:
- Publication type:
- Article
e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 3, p. 779, doi. 10.3390/jcm13030779
- By:
- Publication type:
- Article
Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1338417
- By:
- Publication type:
- Article
Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 2, p. 287, doi. 10.1002/cncr.35021
- By:
- Publication type:
- Article
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 1, p. 273, doi. 10.3390/jcm13010273
- By:
- Publication type:
- Article
One‐month qRT‐PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 6, p. 970, doi. 10.1111/ejh.14085
- By:
- Publication type:
- Article
Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casuality or a new entity?
- Published in:
- Annals of Hematology, 2023, v. 102, n. 10, p. 2963, doi. 10.1007/s00277-023-05329-9
- By:
- Publication type:
- Article
Interferon in chronic myeloid leukaemia: Is it useful for treatment‐free remission?
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 6, p. 1087, doi. 10.1111/bjh.19013
- By:
- Publication type:
- Article
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic‐phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 17, p. 2637, doi. 10.1002/cncr.34923
- By:
- Publication type:
- Article
Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 16, p. 5267, doi. 10.3390/jcm12165267
- By:
- Publication type:
- Article
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 8, p. E204, doi. 10.1002/ajh.26960
- By:
- Publication type:
- Article
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study.
- Published in:
- Cancers, 2023, v. 15, n. 14, p. 3706, doi. 10.3390/cancers15143706
- By:
- Publication type:
- Article
Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1212638
- By:
- Publication type:
- Article
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 11, p. 1704, doi. 10.1002/cncr.34722
- By:
- Publication type:
- Article
Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of Ponatinib and New Compounds.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 6, p. 420, doi. 10.1016/j.clml.2023.03.004
- By:
- Publication type:
- Article
Case Report: Infectious prophylaxis in hematological malignancies.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1163175
- By:
- Publication type:
- Article
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA).
- Published in:
- Annals of Hematology, 2023, v. 102, n. 5, p. 1257, doi. 10.1007/s00277-023-05168-8
- By:
- Publication type:
- Article
The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 3, p. 961, doi. 10.1007/s12325-022-02398-6
- By:
- Publication type:
- Article
Management of polycythemia vera: A survey of treatment patterns in Italy.
- Published in:
- European Journal of Haematology, 2023, v. 110, n. 2, p. 161, doi. 10.1111/ejh.13889
- By:
- Publication type:
- Article
Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 1, p. 50, doi. 10.1002/hon.3087
- By:
- Publication type:
- Article
Asciminib as a third line option in chronic myeloid leukemia.
- Published in:
- International Journal of Hematology, 2023, v. 117, n. 1, p. 16, doi. 10.1007/s12185-022-03432-7
- By:
- Publication type:
- Article
Eine klinische Perspektive auf die Behandlung von chronischer myeloischer Leukämie in der chronischen Phase.
- Published in:
- Kompass Onkologie, 2023, v. 10, n. 1, p. 2, doi. 10.1159/000529704
- By:
- Publication type:
- Article
Editorial: Risk-stratification in myelodysplastic syndromes .
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.1095847
- By:
- Publication type:
- Article
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions.
- Published in:
- Current Hematologic Malignancy Reports, 2022, v. 17, n. 6, p. 198, doi. 10.1007/s11899-022-00683-3
- By:
- Publication type:
- Article
Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience.
- Published in:
- Cancers, 2022, v. 14, n. 19, p. 4897, doi. 10.3390/cancers14194897
- By:
- Publication type:
- Article
Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges.
- Published in:
- International Journal of Hematology, 2022, v. 116, n. 4, p. 586, doi. 10.1007/s12185-022-03370-4
- By:
- Publication type:
- Article
Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 19, p. 5594, doi. 10.3390/jcm11195594
- By:
- Publication type:
- Article
Management of chronic myeloid leukaemia patients treated with ponatinib in a real‐life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA).
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 6, p. 965, doi. 10.1111/bjh.18359
- By:
- Publication type:
- Article
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01309-0
- By:
- Publication type:
- Article
Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance.
- Published in:
- Current Oncology, 2022, v. 29, n. 7, p. 4970, doi. 10.3390/curroncol29070395
- By:
- Publication type:
- Article
Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 13, p. 3597, doi. 10.3390/jcm11133597
- By:
- Publication type:
- Article
Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 6, p. 1275, doi. 10.1007/s00277-022-04815-w
- By:
- Publication type:
- Article
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia.
- Published in:
- Cell Death & Disease, 2022, v. 13, n. 6, p. 1, doi. 10.1038/s41419-022-05028-9
- By:
- Publication type:
- Article
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 9, p. 2596, doi. 10.3390/jcm11092596
- By:
- Publication type:
- Article
Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients.
- Published in:
- Supportive Care in Cancer, 2022, v. 30, n. 5, p. 4303, doi. 10.1007/s00520-021-06782-w
- By:
- Publication type:
- Article
Chronic Myeloid Leukemia Data at ASH 2021: A Podcast on Patient Unmet Needs and Later-Line Treatment Developments.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Le forme de novo della AML-MRC - Pazienti con leucemia ad alto rischio.
- Published in:
- Current Therapeutics, 2022, v. 25, n. 2, p. 3
- By:
- Publication type:
- Article
COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 3, p. 559, doi. 10.1111/bjh.17890
- By:
- Publication type:
- Article
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols.
- Published in:
- Acta Oncologica, 2021, v. 60, n. 11, p. 1520, doi. 10.1080/0284186X.2021.1971291
- By:
- Publication type:
- Article
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
- Published in:
- Acta Oncologica, 2021, v. 60, n. 11, p. 1527, doi. 10.1080/0284186X.2021.1971292
- By:
- Publication type:
- Article
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 4750, doi. 10.3390/cancers13194750
- By:
- Publication type:
- Article
Poster: CML-081: Effect of Comorbidities on Response Outcomes With First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S223, doi. 10.1016/S2152-2650(21)01406-3
- By:
- Publication type:
- Article
Poster: CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S224, doi. 10.1016/S2152-2650(21)01409-9
- By:
- Publication type:
- Article
CML-081: Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S326, doi. 10.1016/S2152-2650(21)01766-3
- By:
- Publication type:
- Article
CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S335, doi. 10.1016/S2152-2650(21)01784-5
- By:
- Publication type:
- Article
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.739171
- By:
- Publication type:
- Article